Back to previous section

4basebio client gets approval to start trial in Australia

4basebio

Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.

4basebio

26 April 2024 17:19:30

Source: Sharecast

The AIM-traded firm said the approval would enable HelixNano to proceed to phase one clinical trials for HN-0001, an mRNA vaccine developed using 4basebio's synthetic DNA technology, ‘opDNA’.

“It’s been a pleasure to work with such an innovative company on their journey to the clinic and we are delighted to see an mRNA vaccine manufactured using 4basebio DNA progressing into patients; this represents another significant milestone for the company,” said the firm’s vice president of research and business development, Dr Amy Walker.

“4basebio has several clients requiring GMP grade DNA and progressing towards clinical trials; we are of course very pleased to be supporting our clients in their clinical programmes.”

At 1529 GMT, shares in 4basebio were up 1.33% at 988p.

Reporting by Josh White for Sharecast.com.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account, Stocks and Shares ISA or a Self-Invested Personal Pension (SIPP), we've got an account to suit your needs.

View our accounts

IWeb is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.